# Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

> **NCT00675350** · PHASE1 · COMPLETED · sponsor: **ChemGenex Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Hematologic Tumors

## Interventions

- **DRUG:** Omacetaxine

## Key facts

- **NCT ID:** NCT00675350
- **Lead sponsor:** ChemGenex Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-09
- **Final completion:** 2009-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675350, "Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00675350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*